Spectral Medical Inc T.EDT

EDEN could be significant in expanding the label

[smartsob]

• EDEN Observational Study
  In March 2022, the Company launched an ancillary observational study, EDEN, to collect data on patients with sepsis even if ineligible for Tigris. EDEN will capture much needed data on the full range of septic shock and its relation to organ failure and endotoxin activity. These data will inform subsequent discussions with the FDA on labelling for PMX as well as to provide the medical community and the Company a better picture of the addressable population in the U.S. for PMX. Furthermore, patients enrolled in EDEN will also be considered for entry into Tigris study, which provides another tool to support enrollment.
  The Company has on boarded 4 EDEN sites and enrolled 17 patients into the observational study.

[Gorf79]

Spectral certainly likes their Biblical references. This study will be very significant I suspect. It may lead to an earlier ending of the trial as well. As always, and as MM said, the share price is whatever they want it to be and today they decided that a 15% haircut after the Veteran's Administration deal was an appropriate close. What else would a 50 cent, 32 person company do after